Moore, N. F., Azarova, A. M., Bhatnagar, N., Ross, K. N., Drake, L. E., Frumm, S., . . . George, R. E. (2014). Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget.
Style de citation ChicagoMoore, Nathan F., et al. "Molecular Rationale for the Use of PI3K/AKT/mTOR Pathway Inhibitors in Combination With Crizotinib in ALK-mutated Neuroblastoma." Oncotarget 2014.
Style de citation MLAMoore, Nathan F., et al. "Molecular Rationale for the Use of PI3K/AKT/mTOR Pathway Inhibitors in Combination With Crizotinib in ALK-mutated Neuroblastoma." Oncotarget 2014.
Attention : ces citations peuvent ne pas être correctes à 100%.